Halozyme Therapeutics (HALO) Free Cash Flow (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Free Cash Flow data on file, last reported at $176.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 15.05% year-over-year to $176.3 million in Q1 2026; TTM through Mar 2026 was $667.7 million, a 31.9% increase from a year earlier, with the FY2025 full-year figure at $644.6 million, up 34.63% from the prior year.
• Free Cash Flow for Q1 2026 stood at $176.3 million, down from $217.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for HALO reached as high as $217.6 million in Q4 2025 and fell as low as $39.1 million in Q2 2022.
• Historically, Free Cash Flow has averaged $112.3 million across 5 years, with a median of $98.1 million in 2025.
• Across the five-year window, Free Cash Flow slumped 43.4% in 2022 and jumped 112.15% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $80.1 million in 2022, then gained by 9.34% to $87.6 million in 2023, then surged by 112.15% to $185.8 million in 2024, then grew by 17.1% to $217.6 million in 2025, then fell by 18.96% to $176.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $176.3 million in Q1 2026, $217.6 million in Q4 2025, and $175.6 million in Q3 2025.